Aldeyra Therapeutics (NASDAQ:ALDX) Director Acquires $128,000.00 in Stock

Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) Director Richard Douglas purchased 200,000 shares of the stock in a transaction that occurred on Wednesday, November 11th. The stock was bought at an average cost of $0.64 per share, with a total value of $128,000.00. Following the acquisition, the director owned 395,000 shares of the company’s stock, valued at $252,800. This represents a 102.56% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is available at the SEC website.

Aldeyra Therapeutics Stock Up 3.1%

NASDAQ:ALDX traded up $0.02 during trading hours on Friday, hitting $0.65. 733,835 shares of the stock were exchanged, compared to its average volume of 1,710,354. The company’s 50 day moving average is $0.99 and its two-hundred day moving average is $2.12. Aldeyra Therapeutics, Inc. has a twelve month low of $0.53 and a twelve month high of $5.93. The company has a market capitalization of $39.23 million, a P/E ratio of -2.03 and a beta of 1.32.

Aldeyra Therapeutics (NASDAQ:ALDX) last announced its quarterly earnings data on Thursday, November 5th. The biotechnology company reported ($0.06) EPS for the quarter, beating analysts’ consensus estimates of ($0.11) by $0.05. On average, equities research analysts expect that Aldeyra Therapeutics, Inc. will post -0.27 EPS for the current year.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in ALDX. Chicago Partners Investment Group LLC bought a new position in shares of Aldeyra Therapeutics in the 1st quarter worth $33,000. Hikari Power Ltd bought a new position in Aldeyra Therapeutics during the 2nd quarter worth approximately $43,000. Two Sigma Securities LLC acquired a new position in Aldeyra Therapeutics during the second quarter valued at approximately $70,000. Bank of America Corp DE acquired a new position in Aldeyra Therapeutics during the second quarter valued at approximately $72,000. Finally, Squarepoint Ops LLC acquired a new position in Aldeyra Therapeutics during the second quarter valued at approximately $200,000. Institutional investors and hedge funds own 59.71% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages have weighed in on ALDX. Weiss Ratings cut Aldeyra Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a report on Monday, September 14th. Wall Street Zen lowered shares of Aldeyra Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, August 15th. HC Wainwright reaffirmed a “neutral” rating and issued a $2.00 target price on shares of Aldeyra Therapeutics in a research note on Wednesday, September 30th. Finally, BTIG Research reiterated a “buy” rating on shares of Aldeyra Therapeutics in a research report on Tuesday, September 29th. One investment analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Aldeyra Therapeutics has a consensus rating of “Hold” and an average target price of $2.00.

Aldeyra Therapeutics Company Profile

Aldeyra Therapeutics, Inc. is a biotechnology company focused on developing treatments for immune-mediated diseases, including conditions affecting the eye. The company’s research centers on reactive aldehyde species (RASP), which it aims to inhibit to address inflammation and related disease processes. Aldeyra’s investigational medicines include reproxalap, a small-molecule RASP inhibitor studied for ocular conditions such as dry eye disease and allergic conjunctivitis. Its pipeline has also included candidates intended to treat systemic immune-mediated conditions.